Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
Reich K, Warren RB, Iversen L, Puig L, Pau-Charles I, Igarashi A, Ohtsuki M, Falqués M, Harmut M, Rozzo S, Lebwohl MG, Cantrell W, Blauvelt A, Thaçi D. Reich K, et al. Among authors: falques m. Br J Dermatol. 2020 Mar;182(3):605-617. doi: 10.1111/bjd.18232. Epub 2019 Jul 18. Br J Dermatol. 2020. PMID: 31218661 Free PMC article.
Quality of life outcomes in adults with moderate-to-severe plaque psoriasis treated with dimethylfumarate (DMF): a post hoc analysis of the BRIDGE study.
van de Kerkhof PCM, Loewe R, Mrowietz U, Falques M, Pau-Charles I, Szepietowski JC. van de Kerkhof PCM, et al. Among authors: falques m. J Eur Acad Dermatol Venereol. 2020 Jan;34(1):119-126. doi: 10.1111/jdv.15922. Epub 2019 Oct 17. J Eur Acad Dermatol Venereol. 2020. PMID: 31465585 Free PMC article. Clinical Trial.
Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2).
Thaci D, Piaserico S, Warren RB, Gupta AK, Cantrell W, Draelos Z, Foley P, Igarashi A, Langley RG, Asahina A, Young M, Falqués M, Pau-Charles I, Mendelsohn AM, Rozzo SJ, Reich K. Thaci D, et al. Among authors: falques m. Br J Dermatol. 2021 Aug;185(2):323-334. doi: 10.1111/bjd.19866. Epub 2021 May 4. Br J Dermatol. 2021. PMID: 33544883 Clinical Trial.
Efficacy and safety of topical finasteride spray solution for male androgenetic alopecia: a phase III, randomized, controlled clinical trial.
Piraccini BM, Blume-Peytavi U, Scarci F, Jansat JM, Falqués M, Otero R, Tamarit ML, Galván J, Tebbs V, Massana E; Topical Finasteride Study Group. Piraccini BM, et al. Among authors: falques m. J Eur Acad Dermatol Venereol. 2022 Feb;36(2):286-294. doi: 10.1111/jdv.17738. Epub 2021 Oct 25. J Eur Acad Dermatol Venereol. 2022. PMID: 34634163 Free PMC article. Clinical Trial.
Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial.
Stockfleth E, von Kiedrowski R, Dominicus R, Ryan J, Ellery A, Falqués M, Ivanoff N, Azeredo RR. Stockfleth E, et al. Among authors: falques m. Dermatol Ther (Heidelb). 2017 Mar;7(1):81-96. doi: 10.1007/s13555-016-0161-2. Epub 2016 Dec 19. Dermatol Ther (Heidelb). 2017. PMID: 27995485 Free PMC article.
Use of reflectance confocal microscopy to evaluate 5-fluorouracil 0.5%/salicylic acid 10% in the field-directed treatment of subclinical lesions of actinic keratosis: subanalysis of a Phase III, randomized, double-blind, vehicle-controlled trial.
Ulrich M, Reinhold U, Falqués M, Rodriguez Azeredo R, Stockfleth E. Ulrich M, et al. Among authors: falques m. J Eur Acad Dermatol Venereol. 2018 Mar;32(3):390-396. doi: 10.1111/jdv.14611. Epub 2017 Oct 19. J Eur Acad Dermatol Venereol. 2018. PMID: 28960520 Clinical Trial.
Erratum to: Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial.
Stockfleth E, von Kiedrowski R, Dominicus R, Ryan J, Ellery A, Falqués M, Ivanoff N, Azeredo RR. Stockfleth E, et al. Among authors: falques m. Dermatol Ther (Heidelb). 2017 Jun;7(2):263. doi: 10.1007/s13555-017-0179-0. Dermatol Ther (Heidelb). 2017. PMID: 28421455 Free PMC article. No abstract available.
19 results